Bold Therapeutics is a clinical-stage pharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company’s lead asset is BOLD-100, a first-in-class ruthenium-based small molecule therapeutic with applications in both oncology and infectious disease.
Bold Therapeutics' development strategy focuses on some of the most challenging cancer indications where existing therapies are largely ineffective, and where BOLD-100 can have the largest impact on patient outcomes. BOLD-100 has a unique mechanism-of-action that is optimal for targeting hard-to-treat cancers. Preclinical and clinical development has demonstrated the potential of BOLD-100 in a wide range of cancer indications and drug combinations. Learn More
BOLD-100 is the most clinically advanced ruthenium-based therapeutics currently in development. BOLD-100 is currently in a Phase 2 clinical trial in combination with FOLFOX for the treatment of advanced gastric, pancreatic, colon and bile duct cancers (NCT04421820). A previously completed Phase 1b trial indicated that BOLD-100 can be safely combined with FOLFOX chemotherapy, with no new Grade 3 or 4 treatment-emergent adverse events; and patients can safely remain on treatment for an extended number of treatment cycles. Learn MoreLearn More